Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05), Zacks reports. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.
Agios Pharmaceuticals Stock Performance
NASDAQ:AGIO traded up $1.47 during trading hours on Friday, hitting $35.22. The company's stock had a trading volume of 1,018,352 shares, compared to its average volume of 758,319. The business's 50-day moving average is $34.29 and its two-hundred day moving average is $43.03. The company has a market capitalization of $2.02 billion, a PE ratio of 3.11 and a beta of 0.88. Agios Pharmaceuticals has a 52-week low of $26.66 and a 52-week high of $62.58.
Wall Street Analyst Weigh In
Several research firms have recently commented on AGIO. StockNews.com cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. Royal Bank of Canada upped their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 10th. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Finally, Scotiabank upped their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a report on Monday, December 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $56.33.
Get Our Latest Analysis on Agios Pharmaceuticals
Insiders Place Their Bets
In other news, insider Tsveta Milanova sold 2,804 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.93% of the stock is currently owned by company insiders.
Agios Pharmaceuticals Company Profile
(
Get Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Further Reading
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
